BioLife Solutions Mathew acquires 45,838, 40,192 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BioLife Solutions EVP & Chief Scientific Officer Aby J. Mathew reported acquiring 45,838 and 40,192 shares of restricted stock on October 6, 2026. The awards vested immediately before the merger’s effective time at approximately 200% of the number of shares granted, based on performance comparisons described in the award terms.
Mathew also reported that 70,000 shares were withheld to cover tax obligations, at a reported price of $38.61 per share, and a disposition of 404,608 shares in connection with the merger’s consummation. At the effective time, each outstanding BioLife common share converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F2 | 45,838 | -- | -- |
| Grant/Award | Common Stock F3 | 40,192 | -- | -- |
| Tax Withholding | Common Stock F4 | 70,000 | $38.61 | $2.70M |
| Disposition | Common Stock F1 | 404,608 | -- | -- |
Footnotes (4)
- F1. Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
- F2. The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
- F3. The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
- F4. Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Key Figures
Key Terms
market-based restricted stock award financial
2023 Omnibus Performance Incentive Plan technical
First Merger Effective Time technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did the BLFS restricted stock awards vest before the merger?
AI-generated analysis. How Rhea-AI works. Not financial advice.